Orthostatic Hypotension clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
open to eligible people ages 30 years and up
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).
Fountain Valley, California and other locations
Our lead scientists for Orthostatic Hypotension research studies include Danielle N. Thordarson, MD.
Last updated: